Cell cycle results indicated that TGF-β1 treatment led to an increased proportion of cells in the G0/G1 phase (61.5 ± 12.8%) compared to the control (45.6 ± 7.0%) and ASC-CM (42.4 ± 16.6%)-treated KCs. This evidence concerns the gene TGFB1 and dry eye syndrome.